Latigo Biotherapeutics Reports Q3 Loss Per Share of $0.55
Story updates
11:53:11 AM UTC
SquawkNews
Latigo Biotherapeutics Q3 Net Loss Narrows 16% to $20.95 Million Latigo Biotherapeutics’ third-q
Related stories
Global Payments reports Q3 revenue of $3.31 billion
M impact | EQUITY | Nov 05, 2026, 11:56 AM UTC
Krispy Kreme Q3 Revenue Falls 12% but Beats Estimates
M impact | EQUITY | Nov 05, 2026, 11:56 AM UTC
Bob's Discount Furniture Q3 Revenue Reaches USD 680.4 Million
Q3 revenue was USD 680.4 million, versus the IBES estimate of USD 666.3 million.
M impact | EQUITY | Nov 05, 2026, 11:56 AM UTC
Citizens Raises Papzimeos Sales Forecast After Precigen Q3 Results
Citizens raised its price target on Precigen after the company reported a better-than-expected third-quarter result led by sales of its RRP drug. The supplied body is truncated bef
M impact | EQUITY | Nov 05, 2026, 11:56 AM UTC
Bob’s Discount Furniture Reports Q3 Gross Profit of $316 Million
M impact | EQUITY | Nov 05, 2026, 11:56 AM UTC
Warby Parker Q3 Revenue Rises as Active Customer Count Grows
M impact | EQUITY | Nov 05, 2026, 11:55 AM UTC